EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Strategic Lowering of LDL-Cholesterol Post Ischemic Stroke: Identifying Optimal Targets, Timing, and Therapeutic Approaches

Nikolaos Gavriil Kolios, Fotios Barkas, George Ntaios iD, Haralampos Milionis

Thrombosis and Haemostasis · 01.03.2026 · 126 (03) · 227-243

DOI: 10.1055/a-2675-0551 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.03.2026. Verfasst von Nikolaos Gavriil Kolios und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medicine, University of Ioanina, Ioannina, Greece. Hauptthemen laut MEDLINE: Cholesterol, LDL, Ischemic Stroke, Dyslipidemias, Anticholesteremic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 91 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stroke remains a leading cause of morbidity and mortality worldwide, with ischemic stroke dominating the landscape. Dyslipidemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is a critical modifiable risk factor in both primary and secondary prevention of stroke. While statins have established their role in stroke prevention, questions remain regarding optimal treatment strategies for specific patient groups, the role of non-statin therapies, and lipid level targets for maximal benefit. Emerging evidence underscores the potential of novel lipid-lowering agents, namely, PCSK9 injectable therapies targeting PCSK9, bempedoic acid, and icosapent ethyl, to complement statins in specific patient groups, including those with statin intolerance, those needing further LDL reduction, and those at high residual risk because of high triglycerides. Furthermore, the variability in stroke subtypes and patient comorbidities highlights the need for individualized, evidence-based approaches to lipid management. This narrative review provides a comprehensive overview of available lipid-lowering therapies for post-stroke patients, proposing practical algorithms for “who” to treat, “how” to treat them, and “how much” LDL-C reduction is needed. We aim to bridge gaps between clinical evidence and practice, focusing on individualized approaches to improve outcomes in this high-risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholesterol, LDLIschemic StrokeDyslipidemiasAnticholesteremic AgentsStrokeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsRisk FactorsTreatment OutcomeProprotein Convertase 9PCSK9 InhibitorsBiomarkers

Substanzen

Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 protein, humanAnticholesteremic AgentsProprotein Convertase 9PCSK9 InhibitorsBiomarkers

Autor:innen und Institutionen

  • Department of Internal Medicine, School of Medicine, University of Ioanina, Ioannina, Greece.
  • 1st Propedeutic Department of Internal Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

ORCID-Profile: George Ntaios

Zitieren

APA

Kolios, N. G., Barkas, F., Ntaios, G., & Milionis, H. (2026). Strategic Lowering of LDL-Cholesterol Post Ischemic Stroke: Identifying Optimal Targets, Timing, and Therapeutic Approaches. Thrombosis and Haemostasis, 126(03), 227-243. https://doi.org/10.1055/a-2675-0551

Vancouver

Kolios NG, Barkas F, Ntaios G, Milionis H. Strategic Lowering of LDL-Cholesterol Post Ischemic Stroke: Identifying Optimal Targets, Timing, and Therapeutic Approaches. Thrombosis and Haemostasis. 2026;126(03):227-243. doi:10.1055/a-2675-0551

BibTeX
@article{Kolios2026,
  author = {Kolios, Nikolaos Gavriil and Barkas, Fotios and Ntaios, George and Milionis, Haralampos},
  title = {Strategic Lowering of LDL-Cholesterol Post Ischemic Stroke: Identifying Optimal Targets, Timing, and Therapeutic Approaches},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  volume = {126},
  number = {03},
  pages = {227--243},
  doi = {10.1055/a-2675-0551}
}
Kostenlos starten →